The FDA clearance and non-dilutive funding de-risk the FSHD program and extend cash runway. Monitor enrollment start for the Phase 2 FSHD trial in Q4 2026 and any DMD data updates from BASECAMP/TRAILHEAD. The $5M milestone structure suggests near-term cash infusions over five quarters.
Price Chart
Executive Summary
Satellos received FDA clearance for its IND application for forazapadin in FSHD, a second degenerative muscle disease with no approved therapies. The FSHD Canada Foundation committed up to US$5 million in non-dilutive milestone payments over five quarters to support a Phase 2 study expected to start in Q4 2026. This expands the pipeline beyond DMD, where preliminary Phase 2 data showed favorable safety and potential muscle regeneration signals.
Key Financial Metrics
Key Facts
- FDA cleared IND for forazapadin in FSHD, a disease with no approved therapies affecting ~800,000 people worldwide.
- FSHD Canada Foundation committed up to US$5 million in non-dilutive milestone payments over five quarters.
- Phase 2 FSHD study (randomized, double-blind, placebo-controlled) expected to start Q4 2026, testing 60 mg and 120 mg doses.
- Forazapadin is already in Phase 2 for DMD (BASECAMP and TRAILHEAD trials); preliminary DMD data showed favorable safety and reduced muscle fat fraction at 60 mg.
- The IND clearance covers a second indication, broadening the therapeutic potential of the AAK1 inhibitor platform.
Financial Impact
Up to US$5 million in non-dilutive milestone payments over five quarters from FSHD Canada Foundation; no revenue or earnings data provided.
Risk Factors
- Phase 2 FSHD trial has not yet begun; enrollment and results are uncertain.
- Preliminary DMD data may not replicate in larger or longer studies.
- No approved therapies exist for FSHD, but competitive landscape includes other experimental approaches.
- Company is clinical-stage with no approved products; reliance on future financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368182 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers